Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy - Yahoo Finance

Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy  Yahoo Finance

Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy - Yahoo Finance

Click here to get full coverage on Will Mineralys Therapeutics (NASDAQ:MLYS) Spend Its Cash Wisely? - simplywall.st

Will Mineralys Therapeutics (NASDAQ:MLYS) Spend Its Cash Wisely?  simplywall.st

Will Mineralys Therapeutics (NASDAQ:MLYS) Spend Its Cash Wisely? - simplywall.st

Click here to get full coverage on MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView

MLYS Stock Price and Chart — NASDAQ:MLYS  TradingView

MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView

Click here to get full coverage on Mineralys Therapeutics Raises Massive $201M as Investors Back Promising Drug Development - Stock Titan

Mineralys Therapeutics Raises Massive $201M as Investors Back Promising Drug Development  Stock Titan

Mineralys Therapeutics Raises Massive $201M as Investors Back Promising Drug Development - Stock Titan

Click here to get full coverage on New Analyst Forecast: $MLYS Given 'Hold' Rating - Nasdaq

New Analyst Forecast: $MLYS Given 'Hold' Rating  Nasdaq

New Analyst Forecast: $MLYS Given 'Hold' Rating - Nasdaq

Click here to get full coverage on (MLYS) Long Term Investment Analysis - news.stocktradersdaily.com

(MLYS) Long Term Investment Analysis  news.stocktradersdaily.com

(MLYS) Long Term Investment Analysis - news.stocktradersdaily.com

Click here to get full coverage on Mineralys Therapeutics: Merits A Small 'Speculative' Holding (NASDAQ:MLYS) - Seeking Alpha

Mineralys Therapeutics: Merits A Small 'Speculative' Holding (NASDAQ:MLYS)  Seeking Alpha

Mineralys Therapeutics: Merits A Small 'Speculative' Holding (NASDAQ:MLYS) - Seeking Alpha

Click here to get full coverage on Mineralys Therapeutics: Navigating Cash Burn and Clinical Triumphs in a $200B Market - AInvest

Mineralys Therapeutics: Navigating Cash Burn and Clinical Triumphs in a $200B Market  AInvest

Mineralys Therapeutics: Navigating Cash Burn and Clinical Triumphs in a $200B Market - AInvest

Click here to get full coverage on Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat - Insider Monkey

Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat  Insider Monkey

Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat - Insider Monkey

Click here to get full coverage on Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March - Yahoo Finance

Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March  Yahoo Finance

Mineralys Therapeutics, Inc. (MLYS): Among Stocks Receiving the Most Insider Love in March - Yahoo Finance

Click here to get full coverage on Mineralys Secures Massive $175M Funding to Accelerate Breakthrough Drug Development - Stock Titan

Mineralys Secures Massive $175M Funding to Accelerate Breakthrough Drug Development  Stock Titan

Mineralys Secures Massive $175M Funding to Accelerate Breakthrough Drug Development - Stock Titan

Click here to get full coverage on Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? - Yahoo Finance

Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds?  Yahoo Finance

Is Mineralys Therapeutics, Inc. (MLYS) a Pump and Dump Stock Favored by Hedge Funds? - Yahoo Finance

Click here to get full coverage on Mineralys Plans $250M Stock Offering to Fund Hypertension Drug Development - Stock Titan

Mineralys Plans $250M Stock Offering to Fund Hypertension Drug Development  Stock Titan

Mineralys Plans $250M Stock Offering to Fund Hypertension Drug Development - Stock Titan

Click here to get full coverage on Here's Why We're Watching Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation - Yahoo

Here's Why We're Watching Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation  Yahoo

Here's Why We're Watching Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation - Yahoo

Click here to get full coverage on Breakthrough: Mineralys Phase 2 Drug Achieves Dual Success in Blood Pressure and Kidney Protection Trial - Stock Titan

Breakthrough: Mineralys Phase 2 Drug Achieves Dual Success in Blood Pressure and Kidney Protection Trial  Stock Titan

Breakthrough: Mineralys Phase 2 Drug Achieves Dual Success in Blood Pressure and Kidney Protection Trial - Stock Titan

Click here to get full coverage on Mineralys Hypertension Drug Shows Strong Results in Two Pivotal Trials - Stock Titan

Mineralys Hypertension Drug Shows Strong Results in Two Pivotal Trials  Stock Titan

Mineralys Hypertension Drug Shows Strong Results in Two Pivotal Trials - Stock Titan

Click here to get full coverage on Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns - Yahoo Finance

Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns  Yahoo Finance

Institutional investors must be pleased after a 8.1% gain last week that adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) one-year returns - Yahoo Finance

Click here to get full coverage on Can This New Hypertension Drug Change Treatment Standards? Key Data Coming - Stock Titan

Can This New Hypertension Drug Change Treatment Standards? Key Data Coming  Stock Titan

Can This New Hypertension Drug Change Treatment Standards? Key Data Coming - Stock Titan

Click here to get full coverage on Breakthrough Phase 3 Results: Novel Drug Shows Powerful 19 mmHg Blood Pressure Reduction in Major JAMA Study - Stock Titan

Breakthrough Phase 3 Results: Novel Drug Shows Powerful 19 mmHg Blood Pressure Reduction in Major JAMA Study  Stock Titan

Breakthrough Phase 3 Results: Novel Drug Shows Powerful 19 mmHg Blood Pressure Reduction in Major JAMA Study - Stock Titan

Click here to get full coverage on Mineralys Therapeutics Inc. (MLYS) reports earnings - Quartz

Mineralys Therapeutics Inc. (MLYS) reports earnings  Quartz

Mineralys Therapeutics Inc. (MLYS) reports earnings - Quartz

Click here to get full coverage on Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - Stock Titan

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update  Stock Titan

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - Stock Titan

Click here to get full coverage on Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell 2000 Value Index - MarketScreener

Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell 2000 Value Index  MarketScreener

Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell 2000 Value Index - MarketScreener

Click here to get full coverage on Breakthrough Phase 3 Trial Data: New Drug Takes Aim at Treatment-Resistant Hypertension Crisis - Stock Titan

Breakthrough Phase 3 Trial Data: New Drug Takes Aim at Treatment-Resistant Hypertension Crisis  Stock Titan

Breakthrough Phase 3 Trial Data: New Drug Takes Aim at Treatment-Resistant Hypertension Crisis - Stock Titan

Click here to get full coverage on Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension - Seeking Alpha

Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension  Seeking Alpha

Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension - Seeking Alpha

Click here to get full coverage on How the (MLYS) price action is used to our Advantage - news.stocktradersdaily.com

How the (MLYS) price action is used to our Advantage  news.stocktradersdaily.com

How the (MLYS) price action is used to our Advantage - news.stocktradersdaily.com

Click here to get full coverage on Breakthrough Hypertension Drug Achieves 15.4 mmHg Blood Pressure Drop in Critical Phase 2 Trial - Stock Titan

Breakthrough Hypertension Drug Achieves 15.4 mmHg Blood Pressure Drop in Critical Phase 2 Trial  Stock Titan

Breakthrough Hypertension Drug Achieves 15.4 mmHg Blood Pressure Drop in Critical Phase 2 Trial - Stock Titan

Click here to get full coverage on Mineralys Therapeutics Reports Positive Phase 2 Trial Results - TipRanks

Mineralys Therapeutics Reports Positive Phase 2 Trial Results  TipRanks

Mineralys Therapeutics Reports Positive Phase 2 Trial Results - TipRanks

Click here to get full coverage on Breakthrough Phase 3 Results: New Drug Cuts Blood Pressure by 19 mmHg in Largest Hypertension Trial - Stock Titan

Breakthrough Phase 3 Results: New Drug Cuts Blood Pressure by 19 mmHg in Largest Hypertension Trial  Stock Titan

Breakthrough Phase 3 Results: New Drug Cuts Blood Pressure by 19 mmHg in Largest Hypertension Trial - Stock Titan

Click here to get full coverage on Breakthrough Hypertension Treatment Shows 15.4 mmHg Blood Pressure Reduction in NEJM-Published Trial - Stock Titan

Breakthrough Hypertension Treatment Shows 15.4 mmHg Blood Pressure Reduction in NEJM-Published Trial  Stock Titan

Breakthrough Hypertension Treatment Shows 15.4 mmHg Blood Pressure Reduction in NEJM-Published Trial - Stock Titan

Click here to get full coverage on Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference - Stock Titan

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference  Stock Titan

Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference - Stock Titan

Click here to get full coverage on Mineralys stock holds Buy rating at H.C. Wainwright after CKD trial - Investing.com

Mineralys stock holds Buy rating at H.C. Wainwright after CKD trial  Investing.com

Mineralys stock holds Buy rating at H.C. Wainwright after CKD trial - Investing.com

Click here to get full coverage on Mineralys Therapeutics to Announce First Quarter 2025 Financial Results on May 12 - Nasdaq

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results on May 12  Nasdaq

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results on May 12 - Nasdaq

Click here to get full coverage on Mineralys Therapeutics: Clinical Catalysts and Capital Efficiency Fuel a Biotech Breakout - AInvest

Mineralys Therapeutics: Clinical Catalysts and Capital Efficiency Fuel a Biotech Breakout  AInvest

Mineralys Therapeutics: Clinical Catalysts and Capital Efficiency Fuel a Biotech Breakout - AInvest

Click here to get full coverage on Mineralys Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock  GlobeNewswire

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire

Click here to get full coverage on Mineralys Therapeutics Approves Key Proposals at Annual Meeting - TipRanks

Mineralys Therapeutics Approves Key Proposals at Annual Meeting  TipRanks

Mineralys Therapeutics Approves Key Proposals at Annual Meeting - TipRanks

Click here to get full coverage on Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update  GlobeNewswire

Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Click here to get full coverage on Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment - MSN

Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment  MSN

Mineralys Therapeutics Publishes Phase 3 Trial Results in JAMA for Hypertension Treatment - MSN

Click here to get full coverage on Mineralys Therapeutics Reports Positive Phase 3 Trial Results - TipRanks

Mineralys Therapeutics Reports Positive Phase 3 Trial Results  TipRanks

Mineralys Therapeutics Reports Positive Phase 3 Trial Results - TipRanks

Click here to get full coverage on Mineralys Therapeutics stock rises on better-than-expected Q1 results - Investing.com

Mineralys Therapeutics stock rises on better-than-expected Q1 results  Investing.com

Mineralys Therapeutics stock rises on better-than-expected Q1 results - Investing.com

Click here to get full coverage on Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET - Yahoo Finance

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET  Yahoo Finance

Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET - Yahoo Finance

Click here to get full coverage on Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 - The Globe and Mail

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025  The Globe and Mail

Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025 - The Globe and Mail

Click here to get full coverage on Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock - GlobeNewswire

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock  GlobeNewswire

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock - GlobeNewswire

Click here to get full coverage on Mineralys sees stock surge on lorundrostat data - The Pharma Letter

Mineralys sees stock surge on lorundrostat data  The Pharma Letter

Mineralys sees stock surge on lorundrostat data - The Pharma Letter

Click here to get full coverage on Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Ex - GlobeNewswire

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Ex  GlobeNewswire

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology’s Annual Scientific Session & Ex - GlobeNewswire

Click here to get full coverage on Mineralys to present lorundrostat trial data at ESH 2025 - Investing.com

Mineralys to present lorundrostat trial data at ESH 2025  Investing.com

Mineralys to present lorundrostat trial data at ESH 2025 - Investing.com

Click here to get full coverage on Earnings call transcript: Mineralys beats Q1 2025 EPS expectations, stock rises - Investing.com

Earnings call transcript: Mineralys beats Q1 2025 EPS expectations, stock rises  Investing.com

Earnings call transcript: Mineralys beats Q1 2025 EPS expectations, stock rises - Investing.com

Click here to get full coverage on Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock - GlobeNewswire

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock  GlobeNewswire

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock - GlobeNewswire

Click here to get full coverage on Mineralys Therapeutics launches $250 million stock offering - Investing.com

Mineralys Therapeutics launches $250 million stock offering  Investing.com

Mineralys Therapeutics launches $250 million stock offering - Investing.com

Click here to get full coverage on Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps - Benzinga

Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps  Benzinga

Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps - Benzinga

Click here to get full coverage on Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat - TipRanks

Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat  TipRanks

Mineralys Therapeutics Unveils Promising Trial Results for Lorundrostat - TipRanks

Click here to get full coverage on Mineralys Therapeutics prices $175M stock offering - MSN

Mineralys Therapeutics prices $175M stock offering  MSN

Mineralys Therapeutics prices $175M stock offering - MSN

Click here to get full coverage on Transcript : Mineralys Therapeutics, Inc. - Special Call - MarketScreener

Transcript : Mineralys Therapeutics, Inc. - Special Call  MarketScreener

Transcript : Mineralys Therapeutics, Inc. - Special Call - MarketScreener

Click here to get full coverage on Jefferies initiates Mineralys Therapeutics stock with hold rating - Investing.com

Jefferies initiates Mineralys Therapeutics stock with hold rating  Investing.com

Jefferies initiates Mineralys Therapeutics stock with hold rating - Investing.com

Click here to get full coverage on Mineralys Therapeutics Inc Says Lorundrostat Shows 16.9 Mmhg Reduction At Week 6, 19.0 Mmhg At Week 12 - MarketScreener

Mineralys Therapeutics Inc Says Lorundrostat Shows 16.9 Mmhg Reduction At Week 6, 19.0 Mmhg At Week 12  MarketScreener

Mineralys Therapeutics Inc Says Lorundrostat Shows 16.9 Mmhg Reduction At Week 6, 19.0 Mmhg At Week 12 - MarketScreener

Click here to get full coverage on Mineralys Therapeutics’ Earnings Call: Positive Outlook Amid Challenges - TipRanks

Mineralys Therapeutics’ Earnings Call: Positive Outlook Amid Challenges  TipRanks

Mineralys Therapeutics, Inc. Common Stock (MLYS)

Price Chart

Key Statistics

Technicals

About MLYS

Latest News

Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy - Yahoo Finance

Will Mineralys Therapeutics (NASDAQ:MLYS) Spend Its Cash Wisely? - simplywall.st

MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView

Advanced Charts

Top Gainers

Top Losers